170 related articles for article (PubMed ID: 34563497)
21. A bromodomain-DNA interaction facilitates acetylation-dependent bivalent nucleosome recognition by the BET protein BRDT.
Miller TC; Simon B; Rybin V; Grötsch H; Curtet S; Khochbin S; Carlomagno T; Müller CW
Nat Commun; 2016 Dec; 7():13855. PubMed ID: 27991587
[TBL] [Abstract][Full Text] [Related]
22. Dietary Compound Resveratrol Is a Pan-BET Bromodomain Inhibitor.
Dutra LA; Heidenreich D; Silva GDBD; Man Chin C; Knapp S; Santos JLD
Nutrients; 2017 Oct; 9(11):. PubMed ID: 29077030
[TBL] [Abstract][Full Text] [Related]
23. Biochemical profiling of histone binding selectivity of the yeast bromodomain family.
Zhang Q; Chakravarty S; Ghersi D; Zeng L; Plotnikov AN; Sanchez R; Zhou MM
PLoS One; 2010 Jan; 5(1):e8903. PubMed ID: 20126658
[TBL] [Abstract][Full Text] [Related]
24. Molecular Basis for the N-Terminal Bromodomain-and-Extra-Terminal-Family Selectivity of a Dual Kinase-Bromodomain Inhibitor.
Divakaran A; Talluri SK; Ayoub AM; Mishra NK; Cui H; Widen JC; Berndt N; Zhu JY; Carlson AS; Topczewski JJ; Schonbrunn EK; Harki DA; Pomerantz WCK
J Med Chem; 2018 Oct; 61(20):9316-9334. PubMed ID: 30253095
[TBL] [Abstract][Full Text] [Related]
25. Bromodomains: Translating the words of lysine acetylation into myelin injury and repair.
Ntranos A; Casaccia P
Neurosci Lett; 2016 Jun; 625():4-10. PubMed ID: 26472704
[TBL] [Abstract][Full Text] [Related]
26. Solution structure of the second bromodomain of Brd2 and its specific interaction with acetylated histone tails.
Huang H; Zhang J; Shen W; Wang X; Wu J; Wu J; Shi Y
BMC Struct Biol; 2007 Sep; 7():57. PubMed ID: 17848202
[TBL] [Abstract][Full Text] [Related]
27. Selective recognition of acetylated histones by bromodomains in transcriptional co-activators.
Hassan AH; Awad S; Al-Natour Z; Othman S; Mustafa F; Rizvi TA
Biochem J; 2007 Feb; 402(1):125-33. PubMed ID: 17049045
[TBL] [Abstract][Full Text] [Related]
28. BET Bromodomain as a Target of Epigenetic Therapy.
Noguchi-Yachide T
Chem Pharm Bull (Tokyo); 2016; 64(6):540-7. PubMed ID: 27250788
[TBL] [Abstract][Full Text] [Related]
29. The exploitation of FRET probes to track bromodomain/histone interactions in cells for bromodomain inhibitors.
Sasaki K; Yoshida M
Drug Discov Today Technol; 2016 Mar; 19():51-56. PubMed ID: 27769358
[TBL] [Abstract][Full Text] [Related]
30. Structure-guided design of potent diazobenzene inhibitors for the BET bromodomains.
Zhang G; Plotnikov AN; Rusinova E; Shen T; Morohashi K; Joshua J; Zeng L; Mujtaba S; Ohlmeyer M; Zhou MM
J Med Chem; 2013 Nov; 56(22):9251-64. PubMed ID: 24144283
[TBL] [Abstract][Full Text] [Related]
31. Identification of unique, differentiation stage-specific patterns of expression of the bromodomain-containing genes Brd2, Brd3, Brd4, and Brdt in the mouse testis.
Shang E; Salazar G; Crowley TE; Wang X; Lopez RA; Wang X; Wolgemuth DJ
Gene Expr Patterns; 2004 Sep; 4(5):513-9. PubMed ID: 15261828
[TBL] [Abstract][Full Text] [Related]
32. Polybromo-1-bromodomains bind histone H3 at specific acetyl-lysine positions.
Chandrasekaran R; Thompson M
Biochem Biophys Res Commun; 2007 Apr; 355(3):661-6. PubMed ID: 17320048
[TBL] [Abstract][Full Text] [Related]
33. Development of novel cellular histone-binding and chromatin-displacement assays for bromodomain drug discovery.
Zhan Y; Kost-Alimova M; Shi X; Leo E; Bardenhagen JP; Shepard HE; Appikonda S; Vangamudi B; Zhao S; Tieu TN; Jiang S; Heffernan TP; Marszalek JR; Toniatti C; Draetta G; Tyler J; Barton M; Jones P; Palmer WS; Geck Do MK; Andersen JN
Epigenetics Chromatin; 2015; 8():37. PubMed ID: 26396593
[TBL] [Abstract][Full Text] [Related]
34. Acetyl-lysine binding site of bromodomain-containing protein 4 (BRD4) interacts with diverse kinase inhibitors.
Ember SW; Zhu JY; Olesen SH; Martin MP; Becker A; Berndt N; Georg GI; Schönbrunn E
ACS Chem Biol; 2014 May; 9(5):1160-71. PubMed ID: 24568369
[TBL] [Abstract][Full Text] [Related]
35. Bromodomains as therapeutic targets in cancer.
Barbieri I; Cannizzaro E; Dawson MA
Brief Funct Genomics; 2013 May; 12(3):219-30. PubMed ID: 23543289
[TBL] [Abstract][Full Text] [Related]
36. Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer.
Faivre EJ; McDaniel KF; Albert DH; Mantena SR; Plotnik JP; Wilcox D; Zhang L; Bui MH; Sheppard GS; Wang L; Sehgal V; Lin X; Huang X; Lu X; Uziel T; Hessler P; Lam LT; Bellin RJ; Mehta G; Fidanze S; Pratt JK; Liu D; Hasvold LA; Sun C; Panchal SC; Nicolette JJ; Fossey SL; Park CH; Longenecker K; Bigelow L; Torrent M; Rosenberg SH; Kati WM; Shen Y
Nature; 2020 Feb; 578(7794):306-310. PubMed ID: 31969702
[TBL] [Abstract][Full Text] [Related]
37. Bromodomain and extraterminal (BET) protein inhibition suppresses human T cell leukemia virus 1 (HTLV-1) Tax protein-mediated tumorigenesis by inhibiting nuclear factor κB (NF-κB) signaling.
Wu X; Qi J; Bradner JE; Xiao G; Chen LF
J Biol Chem; 2013 Dec; 288(50):36094-105. PubMed ID: 24189064
[TBL] [Abstract][Full Text] [Related]
38. Druggability analysis and structural classification of bromodomain acetyl-lysine binding sites.
Vidler LR; Brown N; Knapp S; Hoelder S
J Med Chem; 2012 Sep; 55(17):7346-59. PubMed ID: 22788793
[TBL] [Abstract][Full Text] [Related]
39. Disrupting Acetyl-Lysine Recognition: Progress in the Development of Bromodomain Inhibitors.
Romero FA; Taylor AM; Crawford TD; Tsui V; Côté A; Magnuson S
J Med Chem; 2016 Feb; 59(4):1271-98. PubMed ID: 26572217
[TBL] [Abstract][Full Text] [Related]
40. Bromodomains as therapeutic targets.
Muller S; Filippakopoulos P; Knapp S
Expert Rev Mol Med; 2011 Sep; 13():e29. PubMed ID: 21933453
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
